The Cost-Effectiveness of GaitSmart Rehabilitation Programme

By Staff Writer

April 4, 2024

Understanding GaitSmart Rehabilitation Programme

GaitSmart, a rehabilitation exercise initiative, is designed to address mobility and gait issues. This CE marked class 1 medical device uses sensor-based digital technology. It monitors limb movement and assesses gait, creating a colour-coded report for patients and healthcare professionals. The test takes about 10 minutes and is usable in various settings. This fully automated, innovative technology seeks to improve gait assessment. It also aims to increase access to objective gait analysis, which could improve patient outcomes. In this article we highlight some aspects provided by The National Institute for Health and Care Excellence (NICE) in their recent review of the GaitSmart Rehabilitation Programme and its cost-effectiveness.

Clinical Effectiveness of GaitSmart

The clinical effectiveness of GaitSmart is a crucial factor in its overall value proposition. The technology has shown promising results in improving gait assessment and the choice of intervention, which could lead to improved patient outcomes. The clinical experts have noted that the risk of falls calculated by the external assessment group (EAG) was more realistic than that included in the company’s models. However, the experts have also pointed out the need for more evidence on GaitSmart’s clinical effectiveness, particularly in people at risk of falls. Ongoing and planned pilots evaluating GaitSmart’s use in the National Health Service (NHS) are expected to provide this much-needed evidence.

Cost Analysis of GaitSmart

The GaitSmart program costs about £82.00 per user. This price includes four assessment sessions and the vGym rehabilitation exercise program. It also covers the cost of hiring a healthcare assistant. The cost-saving potential of GaitSmart is significant when compared to standard care, primarily due to the reduced need for healthcare professional time and resources.

Cost Modelling and Savings

The company’s cost model revealed a cost saving of £2.90 per person using GaitSmart for fall risk, and £450.56 per person for hip and knee rehabilitation. The EAG revised these figures. They showed that GaitSmart saves £80.39 compared to standard care for hip or knee replacements. They also showed a saving of £28.70 for people at risk of falls compared to individual physiotherapy. 

Further Evidence and Research

While the current evidence strongly suggests the cost-effectiveness of GaitSmart, further research is needed to solidify these findings. Several ongoing pilots evaluating GaitSmart’s use in the NHS could address existing uncertainties and provide more robust evidence of its benefits.

Reference url

Recent Posts

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

💡 *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

surrogate endpoints guidance
          

Surrogate Endpoints Guidance: New International Report Enhances HTA Practices

🔍 Are surrogate endpoints the key to shaping the future of health technology assessment?

A new report led by NICE reveals standardized guidance for using surrogate endpoints in health economic models, providing clarity and validation tools for HTA decisions. This collaborative effort across multiple global agencies aims to enhance predictions of long-term health benefits from short-term data.

Jump into the article to explore these impactful insights and learn how this guidance is set to improve health technology evaluations!

#SyenzaNews #HealthEconomics #HealthcareInnovation

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.